Dr. Lal Pathlabs Ltd.

NSE: LALPATHLAB | BSE: 539524 | ISIN: INE600L01024 | Industry: Healthcare Services
| Expensive Rocket
1961.3000 37.00 (1.92%)
NSE Sep 24, 2026 15:31 PM
Volume: 430.2K
 

1961.30
1.92%
Emkay
DLPL reported a steady Q4, with EBITDA beating street/our estimates by 6% and adj PAT improving 34% on YoY basis. Strong performance in core markets (Delhi NCR), buoyed by network expansion, offset the persistent muted performance of Suburban (mid-single digit revenue growth).
Number of FII/FPI investors increased from 351 to 357 in Jun 2026 qtr.
More from Dr. Lal Pathlabs Ltd.
Recommended